Coverage window: October 12-18, 2026.
This week put donor-cell selection beside donor matching. In a nonhuman-primate muscle experiment, a highly regenerative iPSC line produced far more donor-derived fibers than a better-matched, weaker line during 28 days of tacrolimus treatment. A separate genome-wide screen traced lipid accumulation in APOE4 oligodendrocytes toward depressed Wnt signaling and GSK3B activity, then followed the signal through iPSC-derived myelinoids and a tau-transgenic mouse model.
Clinical translation also moved, although the evidence remains early. XellSmart reported nine-person dose-escalation data for its iPSC-derived dopaminergic progenitor product and completed enrollment in a 30-person randomized second stage. A new registry record proposes a 205-person, placebo- and sham-controlled test of MSC secretome plus rTMS after stroke. The rest of the issue spans vascularized islet grafts, a planar hPSC hematopoietic niche, and intranasal neural stem cells in a rat model of traumatic brain injury.
1. A high-potency iPSC line outgrafts better-matched muscle cells
Full analysis: A High-Potency iPSC Line Outgrafts Better-Matched Muscle Cells
Primary source: complete *Stem Cell Reports* article
Researchers produced inducible-PAX7 myogenic progenitors from five MHC-typed cynomolgus macaque donors and screened 72 iPSC clones in injured muscles of immunodeficient mice. The spread was large. One 22BP9 clone generated averages of 458 and 477 donor-derived fibers in two muscles, while selected 23CP14 clones remained much weaker.
Three macaques then received four parallel conditions: fully mismatched 22BP9 progenitors, partially matched 23CP14 progenitors, autologous cells, and vehicle. Each cell site received about 102 million progenitors after cardiotoxin injury; tacrolimus continued through the 28-day endpoint. The fully mismatched, high-performing line produced 60, 230, and 97 donor-derived fibers across the three recipients. The partially matched line produced 12, 22, and 15.
The comparison shows how a large potency difference can dominate an early engraftment readout under immunosuppression. It does not establish that MHC matching is unimportant. One strong line was compared with one weak line, the cohort contained three allogeneic recipients, and histologic fiber counts did not measure muscle function, durability, or benefit in muscular dystrophy.
2. A CRISPR screen links APOE4 lipid droplets to Wnt and GSK3B
Full analysis: A CRISPR Screen Connects APOE4 Lipid Droplets to Wnt Signaling
Primary source: peer-reviewed *Cell Stem Cell* article and complete matching bioRxiv manuscript
A genome-wide knockout screen placed 90 million APOE4 iPSC-derived oligodendrocytes into high- and low-lipid bins. Wnt-pathway genes emerged on both sides of the screen. Isogenic ATAC sequencing also found lower accessibility around Wnt and myelination programs in APOE4 cells, and analysis of postmortem cortex from 93 people found a related motif signal in aged human brain.
The authors inhibited GSK3B with CHIR99021. Lipid-droplet burden fell in cultured oligodendrocytes. In 20-week iPSC-derived myelinoids, two weeks of treatment increased myelin-basic-protein immunoreactivity. Short treatment in APOE4;PS19 mice reduced hippocampal lipid staining, while a separate six-week experiment increased myelin staining. Phosphorylated tau did not change in the longer experiment.
These are mechanistic, preclinical results. CHIR99021 is a research compound, GSK3B has broad functions, and the organoid and mouse endpoints were imaging measurements rather than cognition or clinical benefit. The complete experimental detail was available in the matching 2025 preprint; the 2026 journal event is the peer-reviewed publication.
3. XS411 reports an early Parkinson graft signal and closes Phase II enrollment
Primary sources: XellSmart's October 18 release and ClinicalTrials.gov record NCT07080775
XellSmart reported conference data from nine people with moderate-to-advanced Parkinson's disease who received one of three doses of allogeneic iPSC-derived dopaminergic neural progenitors in the bilateral putamen. The phase I portion was open label and used a 3+3 dose-escalation design. The company reported no dose-limiting toxicities, treatment-related serious adverse events, graft-induced dyskinesia, or abnormal overgrowth on available follow-up.
The company also reported an average OFF-state motor-score improvement of more than 30 points and more than five additional hours of good ON time at six months. Those efficacy figures come from a sponsor release and conference presentation; ClinicalTrials.gov has no posted results. Follow-up differed by dose cohort, and there was no concurrent phase I control group.
The same registry now lists 39 participants across the phase I/II program and an active, not-recruiting status. XellSmart says all 30 participants in the randomized, open-label phase II stage have enrolled and that outcome assessment is blinded. That controlled stage, with longer follow-up, will carry more evidentiary weight than the current nine-person signal.
4. Blood-vessel organoids help stem-cell-derived islets survive a mouse graft
Primary source: *Cell Stem Cell* article record
Human pluripotent-stem-cell-derived pancreatic islet organoids were co-cultured with blood-vessel organoids. Capillary networks entered the islet structures and developed fenestrations and molecular features associated with islet endothelium. Beta cells showed partial maturation and greater resistance to hypoxia and endoplasmic-reticulum stress.
After subcutaneous transplantation into diabetic mice, the vascularized organoids survived better, connected with host circulation, and restored long-term normoglycemia, according to the peer-reviewed abstract. The design addresses a practical bottleneck for beta-cell replacement: keeping a metabolically demanding graft alive while host vessels grow in.
The full article was behind publisher access and did not appear in a legitimate open repository when this issue was prepared. Group sizes, follow-up duration, glucose-challenge performance, and adverse histology therefore could not be independently read from the complete methods and results. This brief stays within the abstract and does not treat the mouse result as evidence in people.
5. A flat culture builds a hematopoietic niche around hPSC-derived progenitors
Primary source: *Acta Biomaterialia* article record
A chemically defined, feeder-free protocol directed human pluripotent stem cells through lateral-plate mesoderm and hemogenic endothelium in a two-dimensional culture. The differentiating cells formed an endothelial-stromal microenvironment without aggregates. Across three hPSC lines, as many as 86 percent of cells acquired the CD34-positive, CD43-positive, CD45-positive phenotype within ten days.
Perturbation experiments implicated DLL4/Notch and CXCL12/CXCR4 signaling. The progenitors formed multiple blood lineages in vitro, reached about 80 percent erythroid enucleation, and produced detectable bone-marrow engraftment after transplantation of day-10 CD34-positive cells. Transcriptomic benchmarking still found differences from primary cord-blood long-term HSCs.
This is a manufacturing and developmental platform, rather than a ready replacement product. The full article was behind publisher access and did not appear in a legitimate open repository when this issue was prepared, so this summary does not extend beyond the peer-reviewed abstract. Durable multilineage reconstitution, serial transplantation, and direct comparison with primary HSCs remain decisive tests.
6. One intranasal neural-stem-cell dose shifts TBI-associated signals in rats
Primary source: complete bioRxiv preprint
Seventy immunocompetent rats were randomized across controlled-cortical-impact or sham surgery and LMNSC01 or vehicle groups. Seven days after injury, the treated animals received a single intranasal dose of six million L-MYC-immortalized human neural stem cells. Tissue was collected 39 days later for histology, gene-expression profiling, and multiplex protein measurements.
Male and female rats showed different injury-associated transcriptional programs. Treatment changed partly different pathways in each sex, while two protein signals moved in the same direction: injury-associated ICAM-1 fell and CX3CL1 rose toward sham levels. The paper proposes reduced endothelial activation and altered neuron-microglia communication as candidate mechanisms.
The experiment did not test a functional recovery endpoint, cell persistence, or a dose response. Transcriptomic analyses used subsets of the full cohort, and cross-species cells were studied over a limited interval. The preprint supports a mechanism hypothesis for a minimally invasive delivery route; it does not establish neurological recovery.
7. A controlled stroke study will combine MSC secretome with rTMS
Primary source: complete ClinicalTrials.gov protocol NCT07874269
A newly posted Indonesian study plans to enroll 205 adults one to six months after a first ischemic stroke. Participants will be randomized to eight weekly infusions of MSC-derived secretome plus active 10-Hz rTMS, or saline placebo plus sham stimulation. Participants and outcome assessors are masked. Change in the Fugl-Meyer motor score at eight weeks is the primary endpoint; EEG measures, spasticity, and adverse events are secondary outcomes.
The design is considerably stronger than an uncontrolled MSC study, yet it combines two active components in a single arm. A positive result would not reveal how much came from the secretome, the stimulation, or their interaction. The registry describes a dose of 1.5 billion particle equivalents but provides limited information about source-cell donors, manufacturing, cargo, release specifications, and potency testing. It also lists no data-monitoring committee.
The record was first posted October 14 and remained not yet recruiting. It is a protocol, with no safety or efficacy results.